Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Filters applied. Clear all
. 2019 Jun;9(6):738-755.
doi: 10.1158/2159-8290.CD-18-1220. Epub 2019 Apr 5.

Tissue-Specific Oncogenic Activity of KRAS A146T

Free PMC article

Tissue-Specific Oncogenic Activity of KRAS A146T

Emily J Poulin et al. Cancer Discov. .
Free PMC article


KRAS is the most frequently mutated oncogene. The incidence of specific KRAS alleles varies between cancers from different sites, but it is unclear whether allelic selection results from biological selection for specific mutant KRAS proteins. We used a cross-disciplinary approach to compare KRASG12D, a common mutant form, and KRASA146T, a mutant that occurs only in selected cancers. Biochemical and structural studies demonstrated that KRASA146T exhibits a marked extension of switch 1 away from the protein body and nucleotide binding site, which activates KRAS by promoting a high rate of intrinsic and guanine nucleotide exchange factor-induced nucleotide exchange. Using mice genetically engineered to express either allele, we found that KRASG12D and KRASA146T exhibit distinct tissue-specific effects on homeostasis that mirror mutational frequencies in human cancers. These tissue-specific phenotypes result from allele-specific signaling properties, demonstrating that context-dependent variations in signaling downstream of different KRAS mutants drive the KRAS mutational pattern seen in cancer. SIGNIFICANCE: Although epidemiologic and clinical studies have suggested allele-specific behaviors for KRAS, experimental evidence for allele-specific biological properties is limited. We combined structural biology, mass spectrometry, and mouse modeling to demonstrate that the selection for specific KRAS mutants in human cancers from different tissues is due to their distinct signaling properties.See related commentary by Hobbs and Der, p. 696.This article is highlighted in the In This Issue feature, p. 681.

Conflict of interest statement

Disclosure of Potential Conflicts of Interest: The authors have no conflicts to declare.

Comment in

  • Cancer Discov. 2019 Jun;9(6):681-683
  • RAS Mutations Are Not Created Equal.
    Hobbs GA, Der CJ. Hobbs GA, et al. Cancer Discov. 2019 Jun;9(6):696-698. doi: 10.1158/2159-8290.CD-19-0406. Cancer Discov. 2019. PMID: 31160330

Similar articles

See all similar articles

Cited by 10 articles

See all "Cited by" articles

Publication types

LinkOut - more resources